MarketCapExport financials
Universal Health Services (UHS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Universal Health Services Financial Ratios 2025-2007 | UHS
Brief overview of Universal Health Services's valuation multiples
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The current valuation set is P/E 9.92x (median 10.76x), EV/EBITDA 5.6x (median 5.6x), P/S 0.85x (median 0.8x). On average, multiples differ from their five-year medians by only 0%. Valuation is near its familiar historical range.
The inverse P/E implies an earnings yield of 10.1%. This is not a dividend yield, but current earnings relative to market price.
Capital efficiency is characterized by ROE 20.5%, ROA 9.6%, ROCE 27.4%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
Price, earnings and growth produce a PEG of 0.7x. A value below one indicates moderate pricing relative to expected growth.
The cash return period is stable at 13.8 days initially and 19 days at the end.
What the ratios show
Universal Health Services's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Universal Health Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.9 | 10.5 | 15.9 | 15.8 | 10.8 | 12.3 | 15.4 | 15.9 | 15.6 | 15.6 | 16.4 | 18.6 | 15.5 | 12.4 | 10.1 | 17.6 | 10.6 | 16.2 | - | |
P/S |
0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 1.0 | 1.1 | 1.2 | 1.1 | 1.1 | 1.2 | 1.3 | 1.1 | 0.8 | 0.5 | - | - | - | - |
EPS |
23.4 | 17.2 | 10.3 | 9.2 | 12.0 | 11.1 | 9.2 | 8.3 | 7.9 | 7.2 | 6.9 | 5.5 | 5.2 | 4.6 | 4.1 | 2.4 | 2.6 | 2.0 | - |
EV (Enterprise Value) |
14.6 B | 11.9 B | 11.3 B | 10.6 B | 10.6 B | 10.4 B | 18.5 B | 18.1 B | 17.4 B | 16.6 B | 16.4 B | 15.3 B | 12.9 B | 10.9 B | 9.07 B | 4.03 B | 2.75 B | 3.22 B | -16.4 M |
EBITDA per Share |
41.1 | 34.1 | 25.1 | 21.7 | 23 | 22 | 19.2 | 17.5 | 18.1 | 17.4 | 16.6 | 14.6 | 13.2 | 12.8 | 12.3 | 7.54 | 7.42 | 5.99 | - |
EV/EBITDA |
5.6 | 5.2 | 6.5 | 6.7 | 5.6 | 5.6 | 9.6 | 10.0 | 9.1 | 8.9 | 8.8 | 9.2 | 8.7 | 7.4 | 6.4 | 5.5 | 3.8 | 5.3 | - |
PEG |
0.7 | 0.81 | 2.02 | 3.95 | 1.83 | 2.08 | 1.58 | 2.55 | 1.76 | 3.26 | 0.66 | 3.12 | 1.11 | 1.06 | 0.14 | - | - | - | - |
P/B |
1.0 | 0.8 | 0.8 | 0.8 | 0.8 | 0.9 | 2.3 | 2.3 | 2.3 | 2.4 | 2.6 | 2.7 | 2.4 | 2.0 | 1.7 | 0.5 | 0.7 | - | - |
P/CF |
7.9 | 5.8 | 9.0 | 10.7 | 12.1 | 4.9 | 15.7 | 21.9 | 19.5 | 70.8 | 103.1 | 47.5 | 15.5 | -72.6 | 10.2 | 8.1 | 5.1 | 6.5 | - |
ROE % |
20.46 | 17.13 | 11.67 | 11.41 | 16.28 | 14.94 | 14.80 | 14.47 | 15.08 | 15.49 | 16.01 | 14.60 | 15.71 | 16.34 | 17.34 | 11.63 | 14.87 | 12.58 | - |
ROA % |
9.59 | 7.89 | 5.14 | 5.01 | 7.57 | 7.00 | 6.98 | 6.92 | 6.99 | 6.81 | 7.06 | 6.08 | 6.14 | 5.41 | 5.19 | 3.06 | 6.57 | - | - |
ROCE % |
27.41 | 25.23 | 19.11 | 16.95 | 22.38 | 21.50 | 12.03 | 11.97 | 14.36 | 14.18 | 14.57 | 13.75 | 13.16 | 12.89 | 13.14 | 25.56 | 29.73 | 25.89 | - |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.3 | 1.0 | 1.3 | 1.6 | 1.4 | 1.4 | 1.6 | 1.6 | - | - | - | - |
DSO |
50.2 | 50.9 | 54.4 | 51.3 | 50.2 | 51.9 | 50.1 | 51.2 | 52.6 | 53.8 | 52.6 | 58.1 | 56.0 | 56.0 | 47.2 | - | - | - | - |
DIO |
- | - | - | - | - | - | 46.6 | 46.3 | 45.0 | 44.4 | 43.5 | 44.1 | 45.2 | 45.2 | 8.4 | - | - | - | - |
DPO |
31.2 | 30.2 | 32.1 | 35.0 | 36.4 | 33.1 | 130.4 | 139.2 | 146.0 | 155.6 | 137.2 | 137.1 | 123.1 | 112.8 | 19.7 | 34.6 | 16.1 | - | - |
Operating Cycle |
- | - | - | - | - | - | 96.7 | 97.4 | 97.6 | 98.2 | 96.0 | 102.1 | 101.2 | 101.1 | 55.6 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | -33.7 | -41.7 | -48.4 | -57.4 | -41.2 | -35.0 | -21.9 | -11.6 | 35.8 | -34.5 | -16.1 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Universal Health Services
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
5.25 | 6.01 | 5.71 | 7.150000000000002 | 5.92 | 5.49 | 4.87 | 5.050000000000001 | 3.89 | 4.32 | 3.9 | 3.17 | 2.42 | 2.44 | 2.31 | 2.45 | 2.52 | 2.22 | 2.05 | 3.0299999999999994 | 2.65 | 3.85 | 2.46 | 3.63 | 2.84 | 2.97 | 1.64 | 2.81 | 1.1 | 2.67 | 2.57 | 1.71 | 1.85 | 2.4 | 2.37 | 2.32 | 1.48 | 1.93 | 2.13 | 1.8 | 1.56 | 1.91 | 1.95 | 1.76 | 1.52 | 1.84 | 1.76 | 1.75 | 0.84 | 1.53 | 1.4 | 1.27 | 1.17 | 1.55 | 1.23 | 1.39 | 0.74 | 1.11 | 1.33 | 0.99 | 0.87 | 1.06 | 1.17 | 0.38 | 0.57 | 0.68 |
EBITDA per Share |
10.7 | 11.5 | 10.8 | -1.26 K | 10.8 | 10.1 | 9.28 | -1.86 K | 8.02 | 8.73 | 7.88 | -881 | 6.14 | 6.05 | 5.96 | -571 | 5.81 | 5.12 | 5.02 | -336 | 5.46 | 6.8 | 5.04 | -4.65 K | 5.62 | 5.72 | 4.19 | -825 | 3.53 | 5.24 | 5.07 | -922 | 3.98 | 4.63 | 4.74 | -1.05 K | 3.86 | 4.61 | 4.81 | -5.08 K | 3.93 | 4.48 | 4.72 | -2.86 K | 3.79 | 4.37 | 4.31 | -59.9 K | 2.73 | 3.89 | 3.7 | 4.11 | 3.18 | 3.93 | 3.31 | 2.69 | 2.54 | 3.14 | 3.53 | 2.63 | 2.76 | 3.11 | 3.41 | - | 2.77 | 2.45 K |
ROE % |
19.46 | 20.59 | 20.85 | 20.83 | 19.68 | 18.39 | 17.82 | 17.36 | 15.93 | 14.79 | 13.17 | 11.71 | 11.15 | 11.51 | 11.40 | 11.24 | 12.12 | 12.47 | 14.73 | 15.37 | 16.37 | 16.97 | 16.47 | 15.94 | 15.58 | 13.38 | 13.34 | 14.98 | 13.53 | 14.90 | 14.76 | 14.81 | 16.28 | 16.01 | 15.63 | 15.69 | 15.12 | 15.70 | 16.27 | 16.84 | 17.40 | 17.77 | 18.19 | 18.13 | 18.72 | 17.44 | 17.18 | 16.69 | 15.70 | 16.97 | 17.85 | 17.94 | 19.25 | 18.41 | 17.43 | 18.68 | 17.94 | 19.07 | 19.73 | 20.05 | 17.96 | 16.64 | 14.92 | 2.51 | 2.86 | 3.47 |
ROA % |
9.14 | 9.78 | 9.88 | 9.79 | 9.21 | 8.59 | 8.28 | 8.02 | 7.27 | 6.67 | 5.86 | 5.20 | 4.95 | 5.11 | 5.06 | 5.00 | 5.51 | 5.85 | 7.20 | 7.64 | 8.13 | 8.30 | 7.87 | 7.52 | 7.36 | 6.35 | 6.29 | 7.07 | 6.40 | 7.08 | 7.11 | 7.16 | 7.80 | 7.62 | 7.34 | 7.28 | 6.92 | 7.18 | 7.42 | 7.66 | 7.92 | 8.07 | 8.25 | 8.14 | 8.28 | 7.57 | 7.29 | 6.95 | 6.42 | 6.83 | 6.89 | 6.66 | 6.85 | 6.43 | 5.92 | 6.19 | 5.80 | 6.00 | 6.02 | 5.90 | 5.16 | 5.22 | 5.33 | 0.68 | 1.30 | 1.64 |
ROCE % |
26.47 | 27.75 | 28.00 | 27.94 | 27.89 | 26.43 | 26.03 | 25.58 | 23.92 | 22.84 | 20.75 | 19.19 | 18.23 | 18.23 | 17.61 | 16.91 | 17.60 | 17.87 | 20.59 | 21.17 | 22.57 | 23.42 | 22.95 | 22.79 | 22.44 | 20.10 | 20.21 | 22.02 | 20.67 | 21.94 | 21.63 | 21.82 | 23.77 | 24.26 | 25.01 | 26.07 | 26.19 | 27.19 | 28.06 | 28.87 | 29.51 | 29.85 | 30.35 | 30.42 | 31.45 | 29.72 | 29.73 | 29.35 | 28.20 | 30.48 | 32.32 | 32.90 | 35.47 | 34.70 | 33.60 | 36.01 | 34.98 | 37.27 | 38.77 | 40.09 | 36.58 | 34.83 | 12.17 | - | 5.39 | 6.87 |
DSO |
54.1 | 54.6 | 54.3 | 52.8 | 49.6 | 50.2 | 51.1 | 48.7 | 50.3 | 52.0 | 53.9 | 55.1 | 55.5 | 53.2 | 53.3 | 51.9 | 51.1 | 49.3 | 48.5 | 48.9 | 51.4 | 49.3 | 51.5 | 48.3 | 46.7 | 48.9 | 49.1 | 48.9 | 50.9 | 51.2 | 50.6 | 50.6 | 53.4 | 53.2 | 52.1 | 51.0 | 52.2 | 50.7 | 50.4 | 50.8 | 50.4 | 51.0 | 49.9 | 51.8 | 55.1 | 55.0 | 54.7 | 52.9 | 54.3 | 53.3 | 54.8 | 57.9 | 58.2 | 57.2 | 55.2 | 54.5 | 56.0 | 56.6 | 53.1 | 52.5 | 51.0 | 49.4 | 46.2 | - | - | - |
DPO |
- | - | 16.4 | 16.7 | - | - | 14.8 | 15.1 | - | - | 15.2 | 15.6 | - | - | 16.6 | 17.1 | - | - | 17.8 | 18.5 | - | - | 17.4 | 17.8 | - | - | 14.2 | 14.2 | - | - | 14.9 | 15.3 | - | - | 15.5 | 16.1 | - | - | 16.2 | 17.3 | - | - | 14.6 | 15.5 | - | - | 14.9 | 15.4 | - | - | 13.5 | 14.0 | - | - | 12.5 | 12.9 | - | - | 11.9 | 12.5 | - | - | 13.6 | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Universal Health Services, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Russia
Germany
Britain
China
